RNS Number: 6882Q AstraZeneca PLC 03 June 2024

## **BLOCK LISTING SIX MONTHLY RETURN**

INFORMATION PROVIDED ON THIS FORM MUST BE TYPED OR PRINTED ELECTRONICALLY AND PROVIDED TO AN RIS.

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 3 June 2024

Name of applicant:		ASTRAZENECA PLC		
Name of scheme:		ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL- EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME		
Period of return:	From:	1 DECEMBER 2023	То:	31 MAY 2024
Balance of unallotted securities under scheme(s) from previous return:		4,420,134		
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0		
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		330,091		
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		4,090,043		

Name of contact:	Hannah Tattersall
Telephone number of contact:	+44 (0)746 498 2582

## Astra Zeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit <a href="mailto:astrazeneca.com">astrazeneca.com</a> and follow the Company on social media <a href="mailto:astrazeneca.com"><u>@AstraZeneca.com</u></a>

## Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp Company Secretary AstraZeneca PLC information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.

END

BLRSDAFFFELSEFI